Co-Authors
This is a "connection" page, showing publications co-authored by STEVEN HSESHENG LIN and BRIAN PAUL HOBBS.
Connection Strength
3.533
-
Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival. J R Stat Soc Ser C Appl Stat. 2016 02; 65(2):273-297.
Score: 0.551
-
Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Comprehensive Analysis of Randomized Phase 2B Trial of Proton Beam Therapy Versus Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):368-377.
Score: 0.237
-
Declarations of Independence: How Embedded Multicollinearity Errors Affect Dosimetric and Other Complex Analyses in Radiation Oncology. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1054-1062.
Score: 0.235
-
Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep. 2022 Sep; 3(9):100391.
Score: 0.220
-
The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer. Cancers (Basel). 2022 Mar 03; 14(5).
Score: 0.214
-
Current status and application of proton therapy for esophageal cancer. Radiother Oncol. 2021 11; 164:27-36.
Score: 0.207
-
Identifying Individualized Risk Profiles for Radiotherapy-Induced Lymphopenia Among Patients With Esophageal Cancer Using Machine Learning. JCO Clin Cancer Inform. 2021 09; 5:1044-1053.
Score: 0.207
-
Comparing Radiation Modalities with Trimodality Therapy Using Total Toxicity Burden. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):1001-1005.
Score: 0.192
-
Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579.
Score: 0.187
-
Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. J Thorac Oncol. 2020 01; 15(1):101-109.
Score: 0.180
-
Multimodal Imaging of Pathologic Response to Chemoradiation in Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):996-1001.
Score: 0.162
-
Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation. Int J Part Ther. 2018; 4(3):23-32.
Score: 0.160
-
Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018 07; 128(1):154-160.
Score: 0.160
-
RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. Clin Cancer Res. 2018 01 15; 24(2):341-350.
Score: 0.158
-
Dosimetric and clinical outcomes after volumetric modulated arc therapy for carcinoma of the thoracic esophagus. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):325-332.
Score: 0.152
-
Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80?Years Old. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):811-819.
Score: 0.151
-
An ERK5-NRF2 Axis Mediates Senescence-Associated Stemness and Atherosclerosis. Circ Res. 2023 06 23; 133(1):25-44.
Score: 0.058
-
A hybrid deep learning model for forecasting lymphocyte depletion during radiation therapy. Med Phys. 2022 May; 49(5):3507-3522.
Score: 0.054
-
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021 05; 9(5):467-475.
Score: 0.049